Vaxcyte Advances To Second Stage Of Ongoing Phase 2 Study Evaluating VAX-24 For The Prevention Of Invasive Pneumococcal Disease In Infants
Portfolio Pulse from Benzinga Newsdesk
Vaxcyte has advanced to the second stage of its ongoing Phase 2 study evaluating VAX-24 for the prevention of invasive pneumococcal disease in infants. The initiation of Stage 2 was approved by the Independent Data Safety Monitoring Board following a review of Stage 1 safety and tolerability data. The Stage 2 portion of the VAX-24 infant study will include Prevnar 20® (PCV20) as a study comparator. The company expects to announce topline data from the primary immunization series by 2025, followed by topline data from the booster dose approximately nine months later.
July 11, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxcyte's advancement to the second stage of its Phase 2 study for VAX-24 could potentially impact the company's stock. The inclusion of Prevnar 20® (PCV20) as a study comparator could also have implications for the stock.
The advancement of Vaxcyte's Phase 2 study for VAX-24 to the second stage is a positive development for the company, which could potentially lead to an increase in the company's stock price. The inclusion of Prevnar 20® (PCV20) as a study comparator also adds credibility to the study, which could further boost investor confidence in the company.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100